Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology is viewed favorably because MICVO is showing clinically meaningful activity in a heavily pretreated 2L+ R/M HNSCC population, with a 36% confirmed objective response rate, 94% disease control rate, rapid responses, and 83% of responders achieving more than 50% tumor reduction, all of which suggest real anti-tumor depth rather than isolated signals. The updated dataset also strengthens the investment case by demonstrating subgroup consistency across HPV status, prior EGFR inhibitor exposure, and prior taxane exposure, while the 47% cORR and 8.8-month median PFS in EGFRi-naive patients indicate that the asset may be competitive with the best reported activity in the field. Fundamentally, the outlook is supported by improving tolerability under the dose cap, including a decline in treatment-related discontinuations to 14.3% from 28% and lower Grade 3+ peripheral neuropathy, alongside a large addressable U.S. 2L+ HNSCC population of roughly 29K patients annually and the potential for MICVO to validate EDB+FN as a tractable ADC target and de-risk the broader solid-tumor franchise.

Pyxis Oncology is viewed negatively because its lead asset MICVO still carries substantial clinical and regulatory risk, with the company itself citing the possibility of efficacy failure, safety signals, and commercial competition, while the December 2025 monotherapy update showed a high treatment-related adverse event rate of 89% (16/18), Grade 3/4 TRAEs of 56% (10/18), and a 28% discontinuation rate. The tolerability concerns appear especially concentrated in high-body-weight patients, where all five discontinuations occurred and six of seven Grade 3 payload-related events were observed, underscoring that the program’s therapeutic window remains unproven despite mitigation steps such as dose capping and AIBW dosing. Although the confirmed ORR of 46% (6/13) in 2L+ patients is encouraging, the HPV-positive and HPV-unrelated subgroup results are too small to be decisive, leaving uncertainty over whether MICVO can support broad enough efficacy to overcome safety issues and achieve meaningful commercial traction.